

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended) A method of inducing systemic tolerance to an antigen in an individual in need of such treatment, comprising the step of:

administering to said individual antigen presenting cells which (1) express high levels of Fas ligand ~~resulted~~ resulting from co-infection with AdLoxFasL and AxCANCRe adenoviruses, (2) do not express Fas and (3) express said antigen, wherein said antigen presenting cells induce apoptosis of Fas-positive T-cells directed towards said antigen resulting in said induction of systemic tolerance to said antigen.

Claim 2 (canceled)

Claim 3 (original) The method of claim 1, wherein said antigen is selected from the group consisting of the adenovirus antigen, a viral antigen, an adeno-associated viral antigen, an autoantigen, and an alloantigen.

Claim 4 (original) The method of claim 1, wherein said individual has an autoimmune disease.

Claim 5 (original) The method of claim 4, wherein said autoimmune disease is selected from the group consisting of diabetes, multiple sclerosis, rheumatoid arthritis, thyroiditis, Grave's disease, systemic lupus erythematosus.

Claim 6 (original) The method of claim 1, wherein said individual has had an organ transplant.

Claim 7 (canceled)

Claim 8 (currently amended) The method of claim 1, further comprising the step of delivering *in vitro* to said antigen presenting cells a gene to inhibit apoptosis.

Claim 9 (original) The method of claim 8, wherein said gene to inhibit apoptosis is crmA.

Claim 10-17 (canceled)